Clinical efficacy and safety of valsartan combining amlodipine in treatment of essential hypertension

ZHENG Li

doi:10.3969/j.issn.1674-4055.2016.06.18

Abstract：Objective To discuss the clinical efficacy and safety of valsartan combining amlodipine in patients with essential hypertension.Methods The patients (n=120, male 66, female 54 and aged from 33 to 82) were chosen from Jul. 2013 to Dec. 2014. All patients were randomly divided into observation group (n=60) treated with amlodipine (5 mg/d) and valsartan (80 mg/d) and control group (n=60) treated with amlodipine (5 mg/d) once a day for 4 m. The changes of blood pressure (BP) were detected before and after treatment, curative effect was reviewed, and adverse reactions were recorded after follow-up.Results After treatment for 4 m, systolic blood pressure (SBP) and diastolic blood pressure (DBP) decreased in 2 groups (allP<0.05). SBP [(137.1±16.7) mmHgvs. (126.7±12.3) mmHg and DBP [(93.5±10.5) mmHgvs. (80.4±9.8) mmHg] decreased in observation group compared with control group after treatment (allP<0.05). The total effective rate was higher in observation group than that in control group (95.0%vs. 70.0%) after treatment for 4 m (P<0.05). The difference in the incidence of adverse reactions had no statistical significance between 2 groups (P>0.05).Conclusion Valsartan combining amlodipine can effectively control BP, reduce adverse reactions with higher safety in treatment of essential hypertension, which is well worth clinical application.